Medical cannabis use among patients with chronic pain in an interdisciplinary pain rehabilitation program: Characterization and treatment outcomes

Journal of Substance Abuse Treatment

Volumn 77, Issue , 2017, Pages 95-100

  Shah, Arya ^a   Craner, Julia ^b,c,d   Cunningham, Julie L ^e  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b SPECTRUM HEALTH   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d Mayo Clinic Department of Psychiatry and Psychology   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Cannabis; Chronic pain; Medical marijuana; Pain outcomes; Pain rehabilitation

Indexed keywords

BENZODIAZEPINE; MEDICAL CANNABIS; MORPHINE; OPIATE; DELTA(9)-TETRAHYDROCANNABINOLIC ACID; DRONABINOL; NARCOTIC ANALGESIC AGENT;

ADULT; ALCOHOL ABUSE; ARTICLE; CANNABIS USE; CATASTROPHIZING; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CHRONIC PAIN; CLINICAL ARTICLE; COGNITIVE BEHAVIORAL THERAPY; DEPRESSION; EMOTIONAL STABILITY; FEEDBACK SYSTEM; FEMALE; FUNCTIONAL STATUS; HOSPITAL ADMISSION; HUMAN; MALE; MASS FRAGMENTOGRAPHY; OCCUPATIONAL THERAPY; PAIN SEVERITY; PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHOEDUCATION; QUALITY OF LIFE; RELAXATION TRAINING; SELF REPORT; STRESS MANAGEMENT; SUBSTANCE ABUSE; SUBSTANCE USE; TOBACCO USE; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; INTERDISCIPLINARY COMMUNICATION; MIDDLE AGED; URINE; YOUNG ADULT;

ADULT; AGED; ANALGESICS, OPIOID; CHRONIC PAIN; DRONABINOL; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; MALE; MEDICAL MARIJUANA; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85017234490     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2017.03.012     Document Type: Article

References (38)

1. Abrams, D.I., Jay, C.A., Shade, S.B., Vizoso, H., Reda, H., Press, S.,.. Petersen, K.L., Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68:7 (2007), 515–521.
2. Abrams, D.I., Couey, P., Shade, S.B., Kelly, M.E., Benowitz, N.L., Cannabinoid-opioid interaction in chronic pain. Clinical Pharmacology and Therapeutics 90:6 (2011), 844–851.
3. Bachhuber, M.A., Saloner, B., Cunningham, C.O., Barry, C.L., Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Internal Medicine 174:10 (2014), 1668–1673.
4. Bair, M.J., Wu, J., Damush, T.M., Sutherland, J.M., Kroenke, K., Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosomatic Medicine 70:8 (2008), 890–897.
5. Beeber, L.S., Shea, J., McCorkle, R., The center. The Center for Epidemiologic Studies Depression Scale as a measure of depressive symptom in newly diagnosed patients. Journal of Psychosocial Oncology 1 (1988), 1–20.
6. Breivik, H., Collett, B., Ventafridda, V., Cohen, R., Gallacher, D., Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. European Journal of Pain 10:4 (2006), 287–333.
7. Compton, W.N., Volkow, N.D., Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug and Alcohol Dependence 81 (2006), 103–107.
8. Degenhardt, L., Lintzeris, N., Campbell, G., Bruno, R., Cohen, M., Farrell, M., Hall, & W. D., Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence 147 (2015), 144–150.
9. Devins, G.M., Orne, C.M., Costell, C.G., Binik, Y.M., Measuring depressive symptoms in illness populations: psychometric properties of the Center for Epidemiologic Studies Depression (CES-D) scale. Psychology & Health 2 (1988), 139–156.
10. Dowel, D., Haegerich, T.M., Chou, R., CDC guidelines for prescribing opioids for chronic pain – United States. Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Reports (MMWR) Recommendations and Reports 65 (2016), 1–49.
11. DuPen, S., D. A., Opioid conversion calculator, 2000, Cynergy Group: Poulsbo, WA. Eaton W. W., Muntaner C., Smith C., Tien, A., & Ybarra, M, The Center for Epidemiologic Studies for Depression Scale: review and revision (CESD and CESD-R). Maurish, M.E., (eds.) The Use of Psychological Testing for Treatment Planning and Outcome Assessment, 3rd ed., 2004, Lawrence Erlbaum, Mahwah, NJ, 363–377.
12. Eaton, W.W., Smith, C., Ybarra, M., Muntaner, C., Tien, A., Center for epidemiologic studies depression scale: Review and revision (CESD and CESD-R). 2004.
13. Ellis, G.M. Jr., Mann, M.A., Judson, B.A., Schramm, N.T., Tashchian, A., Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clinical Pharmacology and Therapeutics 38:5 (1985), 572–578.
14. Ellis, R.J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B.,.. Atkinson, J.H., Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34:3 (2009), 672–680.
15. Eriksen, J., Sjogren, P., Bruera, E., Ekholm, O., Rasmussen, N.K., Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 125:1–2 (2006), 172–179.
16. Grant, I., Atkinson, J.H., Gouaux, B., Wilsey, B., Medical marijuana: clearing away the smoke. The Open Neurology Journal 6 (2012), 18–25.
17. Gureje, O., Comorbidity of pain and anxiety disorders. Current Psychiatry Reports 10:4 (2008), 318–322.
18. Hill, K.P., Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 313:24 (2015), 2474–2483.
19. http://www.health.state.mn.us/topics/cannabis/patients/conditions.html.
20. Ilgen, M.A., Bohnert, K., Kleinberg, F., Jannausch, M., Bohnert, A., Walton, M., Blow, F.C., Characteristics of adults seeking medical marijuana certification. Drug and Alcohol Dependence 132 (2013), 654–659.
21. Kerns, R.D., Turk, D.C., Rudy, T.E., West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain 23 (1985), 345–356.
22. Manchikanti, L., Fellows, B., Ailnani, H., Panpati, V., Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 13:5 (2010), 401–435.
23. Manchikanti, L., Helm, S., Fellows, B., Janata, J.W., Pampati, V., Grider, J.A., Boswell, M.V., Opioid epidemic in the United States. Pain Physician 15:Suppl. 3 (2012), ES9–E38.
24. Moeller, K.E., Lee, K.C., Kissack, J.C., Urine drug screening: practical guide for clinicians. Mayo Clinic Proceedings 83:1 (2008), 66–76.
25. Naef, M., Curatolo, M., Teresen-Felx, S., Arendt-Nielsen, L., Zbinden, A., Brenneisen, R., The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105:1–2 (2003), 79–88.
26. OM, I., Relieving pain in America: A Blueprint for Transforming Prevention, Care. Education, and Research, 2011, Institute of Medicine, Washington, DC.
27. Perron, B.E., Bohnert, K., Perone, A.K., Bonn-Miller, M.O., Ilgen, M., Use of prescription pain medications among medical cannabis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use. Journal of Studies on Alcohol and Drugs 76:3 (2015), 406–413.
28. Radloff, L.S., Center for Epidemiological Studies, National Institute of Mental Health, The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement, 1, 1977 (385–01).
29. Roberts, J.D., Gennings, C., Shih, M., Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. European Journal of Pharmacology 530 (2006), 54–58.
30. Schaus, J.F., Sole, M.L., McCoy, T.P., Mullett, N., Bolden, J., Sivasithamparam, J., O'Brien, M.C., Screening for high-risk drinking in a college student health center: characterizing students based on quantity, frequency, and harms. Journal of Studies on Alcohol and Drugs 16 (2009), 34–44.
31. Shaffer, H.J., Nelson, S.E., LaPlante, D.A., LaBrie, R.A., Albanese, M., Caro, G., The epidemiology of psychiatric disorders among repeat DUI offenders accepting a treatment-sentencing option. Journal of Consulting and Clinical Psychology, 75(5), 2007, 795.
32. Sjogren, P., Gronbaek, M., Peuckmann, V., Ekhold, O., A population-based cohort study on chronic pain: the role of opioids. The Clinical Journal of Pain 26:9 (2010), 763–769.
33. Sullivan, M.L.J., Bishop, S.R., Pivik, J., The Pain Catastrophizing Scale: development and validation. Psychological Assessment 7 (1995), 524–532.
34. Sullivan, M.J.L., Stanish, W., Waite, H., Sullivan, M.E., Tripp, D., Catastrophizing, pain, and disability following soft tissue injuries. Pain 77 (1998), 253–260.
35. Townsend, C.O., Kerkvliet, J.L., Bruce, B.K., Rome, J.D., Hooten, W.M., Luedtke, C.A., Hodgson, J.E., A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission. Pain 140 (2008), 177–189.
36. Verra, M.L., Angst, F., Staal, J.B., Brioschi, R., Lehmann, S., Aeschlimann, A., de Bie, R.A., Reliability of the Multidimensional Pain Inventory and stability of the MPI classification system in chronic back pain. BMC Musculoskeletal Disorders 13 (2012), 155–163.
37. Webster, J.M., Oser, C.B., Mateyoke-Scrivner, A., Cline, V.D., Havens, J.R., Leukefeld, C.G., Drug use and criminal activity among rural probationers with DUI histories. International Journal of Offender Therapy and Comparative Criminology 53:6 (2008), 717–730.
38. Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouraux, B., Fishman, S., A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. The Journal of Pain 9:6 (2008), 506–521.